The American Medical Association (AMA) on January 5 criticized the government’s guidelines on quarantine and isolation in the United States, saying the guidance was “confusing” and risked further spread of COVID-19.
For both patients and their healthcare providers (HCPs), the requirement that prior authorizations (PAs) be obtained from health insurers for many branded and specialty medications continues to act as a significant roadblock, according to David Fidler, senior director product innovation at ConnectiveRx.
The American Medical Association (AMA) doubled down on the organization’s stance against using off-label medicines such as hydroxychloroquine and chloroquine to treat COVID-19 patients.
Health investigators are casting a wide net to understand what is sickening hundreds of vapers across the United States and still have not ruled out any product on the market.
The U.S. Senate Finance Committee and the House Oversight Committee started hearings focused on high drug prices.
It’s tough times on Medicine Avenue. But, by aiming to achieve one simple, straightforward metric, I’d argue we could turn every one of those challenges around. That metric is winning a Cannes Lion.
Pharma brands are still spending furiously on DTC – something like a billion dollars more in 2015 than in 2014, with more growth expected this year – and patients are still demanding and sharing more information about drugs and medical conditions, with or without approval from their doctors.
The debate in Washington over drug pricing is getting louder and nastier, and drug marketing is getting caught in the crossfire.
